{"url_path":"/sec/mcrb/8-k/2026-07-08/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","accession_number":"0001193125-26-298525","cik":"0001609809","ticker":"MCRB","issuer_name":"Seres Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","primary_entity_key":"0001609809","primary_entity_name":"Seres Therapeutics, Inc."},"word_count":84,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn July 8, 2026, at the Annual Meeting, a total of 4,985,176 shares of the Company’s common stock were represented in person or by proxy at the meeting, representing approximately 51.75% of the Company’s outstanding Common Stock as of the April 13, 2026 record date. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement."}